204 related articles for article (PubMed ID: 34800005)
1. The effect of surgery plus chemoradiotherapy on survival of elderly patients with stage Ⅱ-Ⅲ esophageal cancer: a SEER-based demographic analysis.
Lv H; Chao C; Wang B; Wang Z; Qian Y; Zhang X
Cancer Med; 2021 Dec; 10(23):8483-8496. PubMed ID: 34800005
[TBL] [Abstract][Full Text] [Related]
2. Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis.
Hong JC; Murphy JD; Wang SJ; Koong AC; Chang DT
Ann Surg Oncol; 2013 Nov; 20(12):3999-4007. PubMed ID: 23800897
[TBL] [Abstract][Full Text] [Related]
3. Prognostic evaluation of esophageal cancer patients with stages I-III.
Qiu MJ; Yang SL; Wang MM; Li YN; Jiang X; Huang ZZ; Xiong ZF
Aging (Albany NY); 2020 Jul; 12(14):14736-14753. PubMed ID: 32701062
[TBL] [Abstract][Full Text] [Related]
4. Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes.
Di Corpo M; Schlottmann F; Strassle PD; Nurczyk K; Patti MG
J Laparoendosc Adv Surg Tech A; 2019 Aug; 29(8):989-994. PubMed ID: 31246532
[No Abstract] [Full Text] [Related]
5. Stage III esophageal adenocarcinoma: definitive chemoradiation vs. chemoradiation plus surgery.
Schlottmann F; Strassle PD; Gaber C; Patti MG
Updates Surg; 2018 Dec; 70(4):423-426. PubMed ID: 29926306
[TBL] [Abstract][Full Text] [Related]
6. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
7. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.
Deng W; Yang Z; Dong X; Yu R; Wang W
Cancer Med; 2021 Jan; 10(2):659-674. PubMed ID: 33314798
[TBL] [Abstract][Full Text] [Related]
8. Prognostic analysis and treatment utilization of different treatment strategies in elderly esophageal cancer patients with distant metastases: a SEER database analysis.
Han LQ; Cui TT; Xiao NJ; Li W
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15413-15423. PubMed ID: 37644234
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and survival in T4b esophageal cancer: a retrospective cohort study.
Yu BB; Huang JQ; Liang HW; Liu Y; Chen L; Pei S; Huang W; Pan XB
Aging (Albany NY); 2024 Apr; 16(8):7131-7140. PubMed ID: 38643464
[TBL] [Abstract][Full Text] [Related]
10. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
11. Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: a SEER-Medicare analysis.
Eil R; Diggs BS; Wang SJ; Dolan JP; Hunter JG; Thomas CR
Cancer; 2014 Feb; 120(4):492-8. PubMed ID: 24194477
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of combined immunotherapy and chemoradiotherapy in locally advanced unresectable esophageal cancer: an analysis based on the SEER database.
Xie L; Zhang Z
Front Immunol; 2024; 15():1334992. PubMed ID: 38292873
[TBL] [Abstract][Full Text] [Related]
13. Influence of adverse effects of neoadjuvant chemoradiotherapy on the prognosis of patients with early-stage esophageal cancer (cT1b-cT2N0M0) based on the SEER database.
Cao X; Wu B; Li H; Xiong J
Front Surg; 2023; 10():1131385. PubMed ID: 37143768
[TBL] [Abstract][Full Text] [Related]
14. Role of Perioperative Chemotherapy in Lymph Node-negative Esophageal Cancer After Resection: A Population-based Study With Propensity Score-matched Analysis.
Yang Y; Zhou X; Tang L; Xu X; Du X; Qiu G
Am J Clin Oncol; 2019 Dec; 42(12):924-931. PubMed ID: 31651453
[TBL] [Abstract][Full Text] [Related]
15. Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer.
Faiz Z; van Putten M; Verhoeven RHA; van Sandick JW; Nieuwenhuijzen GAP; van der Sangen MJC; Lemmens VEPP; Wijnhoven BPL; Plukker JTM
Ann Surg Oncol; 2019 Apr; 26(4):986-995. PubMed ID: 30719634
[TBL] [Abstract][Full Text] [Related]
16. Curative treatment for esophageal cancer: Vancouver Island Cancer Centre experience from 1993 to 1998.
Wilson KS; Wilson AG; Dewar GJ
Can J Gastroenterol; 2002 Jun; 16(6):361-8. PubMed ID: 12096299
[TBL] [Abstract][Full Text] [Related]
17. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study.
Wani S; Drahos J; Cook MB; Rastogi A; Bansal A; Yen R; Sharma P; Das A
Gastrointest Endosc; 2014 Feb; 79(2):224-232.e1. PubMed ID: 24060519
[TBL] [Abstract][Full Text] [Related]
18. Esophageal Cancer Treatment Is Underutilized Among Elderly Patients in the USA.
Molena D; Stem M; Blackford AL; Lidor AO
J Gastrointest Surg; 2017 Jan; 21(1):126-136. PubMed ID: 27527093
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy vs radiotherapy for nonoperative early stage esophageal cancer: A seer data analysis.
Li J; Jia Y; Cheng Y; Wang J
Cancer Med; 2020 Jul; 9(14):5025-5034. PubMed ID: 32441890
[TBL] [Abstract][Full Text] [Related]
20. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
Markar SR; Bodnar A; Rosales J; Song G; Low DE
Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
